The 2024 Ryan White HIV/AIDS Program CLINICAL CONFERENCE

Conference Chairs

Laura W. Cheever, MD, ScM
HIV/AIDS Bureau, The Health Resources and Services Administration
Rockville, MD
Carolyn Chu, MD, MSc
University of California San Francisco
San Francisco, CA
Michael S. Saag, MD
University of Alabama at Birmingham
Birmingham, AL

Speakers

Allison L. Agwu, MD, ScM
The Johns Hopkins University
Baltimore, MD
Constance A. Benson, MD
University of California San Diego
San Diego, CA
Todd T. Brown, MD, PhD
The Johns Hopkins University
Baltimore, MD
Zoobia W. Chaudhry, MBBS
The John Hopkins University
Baltimore, MD
Rajesh T. Gandhi, MD
Harvard University
Boston, MA
Karinn A. Glover, MD, MPH
Albert Einstein College of Medicine
Bronx, NY
Meredith Greene, MD
Meredith Greene, MD
Indiana University
Indianapolis, IN
Joshua P. Havens, PharmD
University of Nebraska Medical Center
Omaha, NE
Toby Maurer, MD
Indiana University
Indianapolis, IN
Michael J. Mugavero, MD, MHSc
University of Alabama at Birmingham
Birmingham, AL
Natalie Neu, MD, MPH
Columbia University
New York, NY
Hyman Scott, MD, MPH
University of California San Francisco
San Francisco, CA
David H. Spach, MD
University of Washington
Seattle, WA
Suman Srinivasa, MD, MS
Harvard Medical School
Boston, MA
Kimberly A. Workowski, MD
Emory University
Atlanta, GA

November 17-19, 2024

Address

Galt House
140 North Fourth St
Louisville
Kentucky
40202
United States

The 2024 RWHAP CLINICAL CONFERENCE will be in-person only. There will not be a virtual component.

This conference is specifically for clinical decision makers (MD/DOs, PAs, and NPs) in RWHAP-funded programs or clinics. A limited number of registration spots are available for registered nurses and pharmacists who serve as the clinical decision makers in their respective RWHAP-funded programs or clinics.

This activity is eligible for CME credits, ABIM MOC points, AAFP credits, nursing credits, and pharmacist credits.

Overview

2024 RWHAP CLINICAL CONFERENCE Description

The 2024 Ryan White HIV/AIDS Program (RWHAP) CLINICAL CONFERENCE will be held in-person in Louisville, Kentucky, from Sunday, November 17, to Tuesday, November 19. The RWHAP CLINICAL CONFERENCE will provide state-of-the-art updates on research, care, and treatment issues in the medical management of HIV infection for experienced HIV clinical decision makers.

The 2024 RWHAP CLINICAL CONFERENCE is planned with and supported by the HIV/AIDS Bureau, Health Resources and Services Administration of the US Department of Health and Human Services (HRSA) and is sponsored and organized by the International Antiviral Society-USA (IAS-USA). This conference is coordinated through the RWHAP AIDS Education and Training Centers (AETC) clinician training network

Participation of clinical decision makers from RWHAP-funded clinics and programs in this educational activity is an integral part of HRSA’s commitment to improving the care and enriching the lives of individuals with HIV. A mix of lectures, case-based interactive presentations, and small-group workshop breakout sessions will be held during the 3 days of the 2024 RWHAP CLINICAL CONFERENCE.

Who Should Attend

Attendance is specifically for HIV clinical decision makers, primarily physicians, nurse practitioners, and physician assistants in Ryan White HIV/AIDS Program (RWHAP)-funded clinics and programs (specifically those operating under part A, B, C, and D), who are responsible for direct patient care and the decisions on clinical care and practice carried out at their clinics.

For those clinics that do not have clinical decision makers or do not have one available at the time to participate, the 2024 RWHAP CLINICAL CONFERENCE offers a limited number of registration spots open specifically for pharmacists and registered nurses who play crucial roles in making clinical decisions within their respective RWHAP-funded clinics or programs. Interested pharmacists and registered nurses should register early since these spots are on a first-come basis.

A key element of the CLINICAL CONFERENCE and integral to HRSA’s commitment to supporting clinicians is that participants from RWHAP-funded clinics or programs are expected to provide relevant updates and training to their clinical colleagues who were unable to attend the conference. Comprehensive resources will be made available to facilitate the development of lectures and educational meetings after the conference.

Each RWHAP-funded clinic (whether through Part A, Part B, Part C, Part D, or a combination of any of these) may register up to 3 eligible staff members to attend.

There is no registration fee to attend.

Learning Objectives

The educational objectives for the 2024 RWHAP CLINICAL CONFERENCE are designed and developed based on the identified needs and knowledge gaps of the attendees.

On completion of the 2024 RWHAP CLINICAL CONFERENCE, participants will be able to:

  • Describe the new aspects and updates to the Ryan White HIV/AIDS Program
  • Identify situations in which the choice of antiretroviral regimen should consider particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
  • Describe the most current data on currently available and investigational new antiretroviral drugs, formulations, and strategies
  • Initiate and monitor HIV prevention intervention strategies, including the use of long-acting injectable preexposure prophylaxis (PrEP), in individuals at risk for HIV infection
  • Describe the current epidemiology, clinical presentations, and management of the most common sexually transmitted infections (STIs) in adults with HIV infection and in special populations such as adolescents
  • Implement key primary care practices
  • Identify available treatment options for managing weight gain, including recent studies of GLP-1 receptor agonists (GLP-1RAs) use among people with HIV, and describe potential clinical challenges with GLP-1RA use
  • Detect and manage opioid use and mental health disorders in people with HIV
  • Describe how diabetes differs in persons with HIV compared to those without HIV, as well as potential connections between antiretroviral therapy and diabetes risk
  • Implement the latest guideline recommendations for treatment, prevention, and management of common HIV-related OIs
  • Describe the clinical challenges in diagnosing neurocognitive disorders in older people with HIV
  • Discuss challenges related to doxycycline postexposure prophylaxis (doxyPEP) for the prevention of chlamydia, gonorrhea, and syphilis

IAS-USA Accreditation Statement

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 18.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Points

ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 18.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA, the CME activity provider, will submit your participant information (eg, name, date of birth, activity credits earned, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.

American Academy of Family Physicians Credits

The AAFP has reviewed The 2024 Ryan White HIV/AIDS Program CLINICAL CONFERENCE and deemed it acceptable for up to 18.25 Live AAFP Prescribed credit(s). Term of Approval is from 11/17/2024 to 11/19/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credits

This activity is eligible for ANCC credit, see final CNE activity announcement for specific details.

Pharmacy Credits

Accreditation Council for Pharmacy Education logoThis activity is eligible for ACPE credit, see final CPE activity announcement for specific details.

Conference Funding

This conference is funded by the Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services (HHS) under grant number U1OHA49824.